"Pluristem can manufacture product at such low cost while keeping up quality and securing regulatory blessing. This will go a long way toward future commercialization. An uncomplimentary comparison between Pluristem and its Australian competitor Mesoblast, Ltd. is not warranted, as Ms. Weinreb likes to think, because in reality the acquisition of stem cells by both companies vastly differs, favoring Pluristem. Their patents for harvesting cells, younger and more vigorous and granted in Mesoblast's own backyard, should result in proof that Pluristem technology is superior."
"Look for the official announcement to come early Summer 2014 ventures Sierra. Sierra and her team continue to closely monitor developments and forecast that the share price of ImmunoCellular Therapeutics will steadily increase hitting $3 by June"